Drugs and therapies – Page 25
-
ArticleYersinia bacteria: can it be eliminated in the intestine?
This article outlines new research from the University of Pennsylvania, concerning Yersinia pseudotuberculosis, a relative of the bacterial pathogen that causes plague by triggering the body’s immune system to form lesions in the intestines.
-
ArticleSARS-CoV-2 spike protein dihedral angle oscillations reveal favoured rotation frequencies
As new variants of the SARS-CoV-2 virus emerge, leading scientists Dr Oscar Bastidas and Dr Zoran Sevarac explore how their latest research identified a structured frequency domain profile in data with no discernible pattern. Their article also emphasises that it remains imperative to continue learning about this pathogen’s molecular machinery ...
-
ArticleAn approach to mRNA vaccine development in the wake of COVID-19
Brad Sorenson, CEO of Providence Therapeutics, shares the future developments and exciting potential of mRNA therapies, including improved efficacy and wider access to vaccines, and future promise for cancer treatment.
-
ArticleDe-risking drugs in multiplex assays before progressing to clinical trials
Sheraz Gul, Head of Assay Development and Drug Repurposing at the Fraunhofer Institute, discusses the importance of performing comprehensive multiplex spatial and temporal profiling of drugs in pre-clinical research to decrease the risk of potentially undesirable events in later clinical studies.
-
ArticleDrug Target Review Vaccine development ebook 2023
In this ebook are articles on the future potential for mRNA therapies and combatting new variants of the SARS-CoV-2.
-
ArticleDrug Target Review - Issue 1 2023
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
-
ArticleWomen in STEM with Lindsey Clarke: ‘everyone has half an hour’
For International Women's Day, Drug Target Review’s Izzy Wood recently spoke to Lindsey Clarke about her experience as a woman in STEM.
-
VideoWebinar: Accurate detection of mitochondrial toxicity
Using Agilent Seahorse XF technology with the XF Mito Tox Assay allows for streamlined, reliable identification of mitochondrial toxicants.
-
VideoVideo: Spatial imaging as a tool for discovery
Watch Dr David Rimm from the Yale School of Medicine talk about his recent work and take on the future of multiplex spatial profiling of the TME.
-
ArticleLatest in lab automation
In this article Drug Target Review's Izzy Wood highlights three of the latest findings using lab automation techniques and technologies that aid scientists.
-
ArticleOvarian cancer breakthrough: the potential of rhenium tricarbonyl (TRIP) as a promising anti-tumour drug
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.
-
ArticleTransforming the way cancer vaccines are designed and made
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
-
ArticleArtificial intelligence: a great crash of hype into reality
Technology is infamous for falling into a hype cycle, with its peaks and valleys of exaggerated expectations and disillusionment — AI-driven drug discovery is no exception. In this article, Aaron Daugherty, Vice President Discovery at Aria Pharmaceuticals, highlights how the industry can use AI to transform research.
-
Article2023 and beyond: revolutionising drug discovery
Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and ...
-
ArticleDeveloping state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
-
ArticleAllogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
-
ArticleTransformational vaccines that address global health challenges
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
-
Article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
-
Article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
-
ArticleCould drinking green tea, red wine and beer prevent Alzheimer’s?
In this article, Drug Target Review’s Izzy Wood reviews some of the latest Alzheimer's disease research, highlighting the progress that has been made toward new, more unique therapeutic strategies against Alzheimer’s.